Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy

This study assessed the cost–effectiveness of abatacept relative to adalimumab for RA in Italy based on a head-to-head trial by means of a cost–consequence analysis. Results : Health benefits based on the most stringent efficacy criteria were in favor of abatacept compared to adalimumab. Rates for more costly adverse events were higher for adalimumab compared to abatacept, which was reflected in the lower costs for abatacept (-€237,246 or -€237per patient).

Conclusion : The health economic value of abatacept compared with adalimumab from the perspective of the Italian NHS depends on the choice of health outcome. Health gains with abatacept were generally based on more stringent criteria and lower total costs.